News Releases
View all Historical Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 27, 2021Live fireside chat with Dr. Christopher J. Schaber, President and Chief Executive Officer of Soligenix on Wednesday, September 29 at 8:00 AM ET
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Sep 16, 2021- Validated clinical pharmacology and positive psoriasis proof-of-concept clinical study with synthetic hypericin sets stage for pipeline expansion
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Sep 9, 2021Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Aug 23, 2021Single-vial vaccine platform demonstrates high antibody levels against three lethal viruses
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
-
Aug 18, 2021Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates- Potent efficacy data using purified antigens and CoVaccine HT™ adjuvant demonstrated in non-human primates (NHPs) published in Frontiers in Immunology
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...